FOLH1 and prostate cancer: PET/CT using radionuclide- labeled PSMA small-molecule inhibitors ([68Ga]Ga- PSMA - 11) has shown remarkable sensitivity and specificity in the diagnosis, staging, restaging, and prognosis assessment of prostate cancer (13, 14).